A multicenter, randomized, double-blind phase III study of HBI-8000 combined with nivolumab versus placebo with nivolumab in patients with unresectable or metastatic melanoma not previously treated with PD-1 or PD-L1 inhibitors

被引：0
|
作者：
Khushalani, N. I. [1 ]
Shue, H. [2 ]
Gedye, C. [3 ]
Mazumder, A. [4 ]
Sharma, S. [5 ]
Eastgate, M. [6 ]
Majem Tarruella, M. [7 ]
Antonanzas Basa, M. [8 ]
Montaudie, H. [9 ]
Marais-Nieman, R. [10 ]
de la Cruz Merino, L. [11 ]
Clements, A. [12 ]
Mortier, L. [13 ]
Jameson, M. [14 ]
Shojaei, F. [15 ]
Ning, J. [16 ]
Aiyer, L. [17 ]
Gillings, M. [17 ]
Kabbinavar, F. [18 ]
Ascierto, P. [19 ]
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Cutaneous Oncol, Magnolia Campus, Tampa, NY USA
[2] Sunshine Coast Haematol & Oncol Clin, Med Oncol, Buderim, Qld, Australia
[3] Calvary Mater Hosp Newcastle, Med Oncol Dept, Newcastle, NSW, Australia
[4] Oncol Inst Hope & Innovat, Med Oncol, Fountain Valley, CA USA
[5] Ballarat Base Hosp, Ballarat Hlth Serv, Med Oncol, Ballarat, Vic, Australia
[6] Royal Brisbane & Womens Hosp, Med Oncol, Herston, Qld, Australia
[7] Hosp Santa Creu & Sant Pau, Med Oncol, Barcelona, Spain
[8] Univ San Carlos, Hosp Clin, Med Oncol Dept, Madrid, Spain
[9] Hop Archet, Dermatol, Nice, France
[10] Curo Oncol Marais R, Radiat Oncol Dept, Pretoria, South Africa
[11] Hosp Univ Virgen Macarena, Med Oncol, Seville, Spain
[12] Sydney Adventist Hosp, Med Oncol, Wahroonga, NSW, Australia
[13] Hop Roger Salengro, CHRU Lille, Med Oncol, Lille, France
[14] Waikato Hosp, Med Oncol, Hamilton, New Zealand
[15] HUYA Biosci Int, Preclin Dev, San Diego, CA USA
[16] HUYABIO Int LLC, Oncol Clin Dev, San Diego, CA USA
[17] HUYA Biosci Int, San Diego, CA USA
[18] HUYA Biosci Int, Global Res & Dev, San Diego, CA USA
[19] Ist Nazl Tumori Fdn G Pascale, Med Oncol, Naples, Italy
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.10.052
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
42TIP
引用
收藏
页码：S1444 / S1444
页数：1
相关论文
共 50 条
  • [1] Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial
    VanderWalde, Ari
    Bellasea, Shay L.
    Kendra, Kari L.
    Khushalani, Nikhil I.
    Campbell, Katie M.
    Scumpia, Philip O.
    Kuklinski, Lawrence F.
    Collichio, Frances
    Sosman, Jeffrey A.
    Ikeguchi, Alexandra
    Victor, Adrienne I.
    Truong, Thach-Giao
    Chmielowski, Bartosz
    Portnoy, David C.
    Chen, Yuanbin
    Margolin, Kim
    Bane, Charles
    Dasanu, Constantin A.
    Johnson, Douglas B.
    Eroglu, Zeynep
    Chandra, Sunandana
    Medina, Egmidio
    Gonzalez, Cynthia R.
    Baselga-Carretero, Ignacio
    Vega-Crespo, Agustin
    Garcilazo, Ivan Perez
    Sharon, Elad
    Hu-Lieskovan, Siwen
    Patel, Sapna P.
    Grossmann, Kenneth F.
    Moon, James
    Wu, Michael C.
    Ribas, Antoni
    [J]. NATURE MEDICINE, 2023, 29 (09) : 2278 - +
  • [2] Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial
    Ari VanderWalde
    Shay L. Bellasea
    Kari L. Kendra
    Nikhil I. Khushalani
    Katie M. Campbell
    Philip O. Scumpia
    Lawrence F. Kuklinski
    Frances Collichio
    Jeffrey A. Sosman
    Alexandra Ikeguchi
    Adrienne I. Victor
    Thach-Giao Truong
    Bartosz Chmielowski
    David C. Portnoy
    Yuanbin Chen
    Kim Margolin
    Charles Bane
    Constantin A. Dasanu
    Douglas B. Johnson
    Zeynep Eroglu
    Sunandana Chandra
    Egmidio Medina
    Cynthia R. Gonzalez
    Ignacio Baselga-Carretero
    Agustin Vega-Crespo
    Ivan Perez Garcilazo
    Elad Sharon
    Siwen Hu-Lieskovan
    Sapna P. Patel
    Kenneth F. Grossmann
    James Moon
    Michael C. Wu
    Antoni Ribas
    [J]. Nature Medicine, 2023, 29 : 2278 - 2285
  • [3] A phase III, randomized, double-blind study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus dacarbazine in patients (pts) with previously untreated, unresectable, or metastatic melanoma (MEL).
    Robert, Caroline
    Ascierto, Paolo Antonio
    Maio, Michele
    Hernberg, Micaela
    Schmidt, Henrik
    Waxman, Ian
    Garbe, Claus
    Lebbe, Celeste
    Hauschild, Axel
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [4] CA224-047: A randomized, double-blind, phase II/III study of relatlimab (anti-LAG-3) in combination with nivolumab (anti-PD-1) versus nivolumab alone in previously untreated metastatic or unresectable melanoma
    Lipson, E. J.
    Long, G. V.
    Tawbi, H.
    Schadendorf, D.
    Atkinson, V. G.
    Maurer, M.
    Simonsen, K. L.
    Harbison, C.
    Hodi, F. S.
    [J]. ANNALS OF ONCOLOGY, 2018, 29
  • [5] Anti PD-1 (nivolumab, pembrolizumab) or anti PD-L1 (atezolizumab) versus docetaxel for previously treated patients with advanced NSCLC: A meta -analysis.
    Des Guetz, Gaetan
    Landre, Thierry
    Nicolas, Patrick
    Vergnenegre, Alain
    Chouaid, Christos
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [6] PD-1/PD-L1 Inhibitors versus Chemotherapy for Previously Treated Advanced Gastroesophageal Cancer: A Meta-Analysis of Randomized Controlled Trials
    Zhong Maoxi
    Xue Jinmin
    Zeng Xiaozhu
    Yue Yubing
    Zhu Yuxi
    [J]. JOURNAL OF ONCOLOGY, 2021, 2021
  • [7] High clinical efficacy in poor prognosis patients with metastatic melanoma treated with an IDO/PD-L1 peptide vaccine in combination with nivolumab
    Kjeldsen, Julie W.
    Lorentzen, Cathrine L.
    Martinenaite, Evelina
    Ellebaek, Eva
    Donia, Marco
    Ehrnrooth, Eva
    Andersen, Mads H.
    Svane, Inge Marie
    [J]. CANCER RESEARCH, 2022, 82 (12)
  • [8] Phase 2 Study of Nivolumab and Metformin in Advanced Non-Small Cell Lung Cancer with and without Prior Treatment with PD-1/PD-L1 Inhibitors
    Chae, Y.
    Iams, W.
    Pai, S.
    Costa, R.
    Taxter, T.
    Mohindra, N.
    Villaflor, V.
    Pro, B.
    Giles, F.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1973 - S1973
  • [9] A multicenter, single-arm, phase II study of nivolumab in patients with biliary tract cancer with a PD-L1 combined positive score ≥ 1.
    Furukawa, Masayuki
    Ueno, Makoto
    Sakai, Daisuke
    Ouchi, Kota
    Hamamoto, Yasuo
    Aikata, Hiroshi
    Ozaka, Masato
    Tsumura, Hidetaka
    Tsuji, Kunihiro
    Kubo, Shoji
    Nishina, Tomohiro
    Katanuma, Akio
    Morizane, Chigusa
    Ikeda, Masafumi
    Mizuno, Nobumasa
    Inagaki, Takashi
    Shioji, Kazuhiko
    Furuse, Junji
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 533 - 533
  • [10] A randomized phase 2 study of nivolumab and nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases: The Anti-PD1 Brain Collaboration (ABC Study).
    Long, Georgina V.
    Atkinson, Victoria
    Menzies, Alexander M.
    Guminski, Alexander David
    Sandhu, Shahneen Kaur
    Brown, Michael Paul
    Liaw, Tracy
    Gonzalez, Maria
    Davison, Jill
    Paton, Elizabeth J.
    Scolyer, Richard A.
    Emmett, Louise
    McArthur, Grant A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345